Haemostatix is developing a new class of coagulant for the control of surgical bleeding. The company's lead product, PeproStat, has recently completed a clinical trial in liver surgery patients. PeproStat is based on a peptide conjugated to recombinant albumin, and is formulated as a sterile solution that is applied topically to an internal wound. We are now gearing up to progress the product into Phase IIb and beyond. We have a highly innovative platform technology and an exciting pipeline. Our second product, HXP12 ReadyFlow is a purely synthetic peptide formulated in a gel, and is at a pre-clinical stage.
We are looking for an individual with substantial drug program management experience, spanning pre-clinical through to Phase III. The candidate will be the PeproStat program manager, and will also manage the safety and toxicology studies for HXP12 ReadyFlow. The candidate will have a minimum of 15 years’ experience in the pharmaceutical / biopharmaceutical industry.